Latest:
Expert Discusses Improving MRI Testing for Prostate Cancer
Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses improving MRI testing for patients with prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Andrew X. Zhu, MD
Latest:
Dr. Zhu on Optimal Second-Line Treatment for Patients With HCC
Andrew X. Zhu, MD, PhD, professor of Medicine, Harvard Medical School, director of Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the possibility of an optimal second-line treatment for all patients with hepatocellular carcinoma (HCC).
Andy Hahn, MD
Latest:
Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an Option
Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.
Anees B. Chagpar, MD
Latest:
Dr. Chagpar on Novel Agents for Neoadjuvant TNBC Treatment
Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, discusses novel agents for neoadjuvant triple-negative breast cancer (TNBC) treatment.
Anees B. Chagpar, MD, MSc, MPH, MA, MBA
Latest:
Intraoperative Shave Technique Proves Effective in Breast-Conserving Surgery
Data from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.
Angela Dispenzieri, MD
Latest:
Dr. Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in Myeloma
Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses excitement over the development of CD38-targeted monoclonal antibodies as treatments for patients with multiple myeloma.
Angela Mae Obermiller, PharmD
Latest:
The Longstanding Quest for a Better Endocrine Therapy Continues High-Dose Fulvestrant: Have We Found Its Effective Dose, Combination, Setting, or Sequence?
Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.